Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins FLT3 D835Y TP53 wild-type |
| Therapy | Milademetan + Quizartinib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 D835Y TP53 wild-type | acute myeloid leukemia | sensitive | Milademetan + Quizartinib | Preclinical - Pdx | Actionable | In a preclinical study, treatment with the combination of Vanflyta (quizartinib) and Milademetan decreased leukemia burden and improved survival compared to either drug alone in a patient-derived xenograft (PDX) model of TP53 wild-type acute myeloid leukemia harboring a FLT3-ITD mutation and FLT3 D835Y (PMID: 40327322). | 40327322 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40327322) | Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias. | Full reference... |